Wells Fargo
SPRB

Wells Fargo’s Spruce Biosciences SPRB Stock Holding History

Wells Fargo’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$112 – 7590
2024
Q1 		$112 Hold
2
– – ﹤0.01% 6628
2023
Q4 		$413 Hold
2
– – ﹤0.01% 6430
2023
Q3 		$294 Hold
2
– – ﹤0.01% 6486
2023
Q2 		$400 Buy
2
+1
+100% +$167 ﹤0.01% 6536
2023
Q1 		$148 Sell
1
-5
-83% -$929 ﹤0.01% 6846
2022
Q4 		$511 Sell
6
-3
-33% -$251 ﹤0.01% 6378
2022
Q3 		$1K Sell
9
-5
-36% -$699 ﹤0.01% 6498
2022
Q2 		$2K Sell
14
-51
-78% -$6.53K ﹤0.01% 6395
2022
Q1 		$10K Sell
65
-61
-48% -$11.3K ﹤0.01% 6276
2021
Q4 		$43K Sell
126
-20
-14% -$5.95K ﹤0.01% 6041
2021
Q3 		$66K Buy
146
+52
+55% +$32.6K ﹤0.01% 5532
2021
Q2 		$79K Buy
94
+65
+224% +$69.4K ﹤0.01% 5388
2021
Q1 		$36K Sell
29
-21
-42% -$32.2K ﹤0.01% 5967
2020
Q4 		$90K Buy
+50
New +$82.9K ﹤0.01% 5403

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Wells Fargo's SPRB Position: Q2 2024 in Review

Wells Fargo sold out of Spruce Biosciences (SPRB) in Q2 2024, closing a stake of 2 shares — an estimated $112 sold.

Wells Fargo first reported a position in SPRB in Q4 2020 and held it in 14 quarters. The position peaked at $90K in Q4 2020. 37 funds tracked by Wall St. Rank hold SPRB as of Q2 2024.

  • Wells Fargo reported no remaining Spruce Biosciences position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 2 Spruce Biosciences shares in Q2 2024, an estimated $112.
  • Wells Fargo first reported a position in Spruce Biosciences in Q4 2020 and held it in 14 quarters.
  • Wells Fargo's Spruce Biosciences position peaked at $90K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.